1. Combined therapy with Sorafenib and FAK inhibitor TAE226 impairs hepatocellular carcinoma growth by interfering with epigenetic modifications and stemness markers. (February 2019) Authors: Romito, I.; Braghini, R.; Panera, N.; Pompili, L.; Crudele, A.; De Stefanis, C.; Porru, M.; Leonetti, C.; Alisi, A. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OC-05The nexus between LncOb rs10487505 variant, leptin levels and non-alcoholic fatty liver disease in children and adolescents. (October 2021) Authors: Manco, M.; Crudele, A.; Mosca, A.; Caccamo, R.; Braghini, R.; De Vito, R.; Alterio, A.; Sartorelli, R.; Pizzolante, F.; De Peppo, F.; Alisi, A. Journal: Digestive and liver disease Issue: Volume 53(2021)Supplement 4 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗